about
Exposure to nerve growth factor worsens nephrotoxic effect induced by Cyclosporine A in HK-2 cellsEndoplasmic reticulum stress and unfolded protein response in renal pathophysiology: Janus facesPharmGKB summary: cyclosporine and tacrolimus pathwaysAssessment of islet function following islet and pancreas transplantationTacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipientsGreen tea polyphenols stimulate mitochondrial biogenesis and improve renal function after chronic cyclosporin a treatment in ratsUrinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation.Genomic-derived markers for early detection of calcineurin inhibitor immunosuppressant-mediated nephrotoxicityCyclosporine: a review.Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized studyPatient-specific prediction of ESRD after liver transplantation.Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.The unfolded protein response triggered by environmental factors.Sublingual administration of tacrolimus: current trends and available evidence.Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.How does age affect the outcome of kidney transplantation in elderly recipients?Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases.Suppression of Primary Splenocyte Proliferation by Artemisia capillaris and Its Components.Augmented renal clearance in the critically ill: how to assess kidney function.Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change.Orally Disintegrating Tablets Containing Melt Extruded Amorphous Solid Dispersion of Tacrolimus for Dissolution Enhancement.
P2860
Q28534915-A0C6DD00-FD49-4516-B496-64900E7CCBB5Q30039723-47E54476-BF3A-43D8-8700-F6E43979D66BQ33989902-2D5D7BDA-32CE-486A-BD50-4BD3D9D5536EQ34086645-16134855-3E94-40CA-8108-8A81BBBF34B4Q34497165-5E38EB04-D4C2-4FF9-AA5E-63783A6F82D9Q34766031-401D7D8E-AD7F-4EAC-940A-56B9B1589491Q35133090-BB221FC0-F570-4B70-8B79-258A3A846BF0Q35385844-F57ED485-C141-4E37-B137-26B28DD53384Q35675934-40E90FA7-9271-444E-8628-18E493A7190EQ37022116-148504F9-FCCA-429B-816E-26C15EA27DF8Q37340234-36FED6E7-0157-4234-9D4C-C2FCBAB68121Q37680948-C437852C-118B-461A-9480-4BA14611AA1DQ37892910-E3F74DFE-816E-44B8-9A34-8B0F3B713744Q38057373-565501D5-CE3B-4025-B9B2-91F00461CC23Q38095787-2A398E77-7CCE-4191-8471-FF8967A32E60Q38253944-6BD22343-03BD-486D-8386-B9513D978195Q38435024-773895BC-30F4-4DEC-B3F5-8F51D60A0874Q40162118-DA5D4F21-9489-49CA-9E8C-88A37E1A1698Q40186826-23701355-4ED9-41E4-8531-BD2C81DAA300Q42642858-DDC0FA45-855E-43FC-9163-61837A8E968DQ50937157-5F0EBD57-8D5C-4A97-8BB3-46E04CA9D28CQ51101954-8BCADBEE-6812-4569-A323-5C931CD8D114Q53151509-2717EFB6-3E36-4AAB-A311-CE710B8EB94AQ55341961-37382EE8-D8FE-42DC-9F20-309407CCD5B2
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Calcineurin nephrotoxicity.
@ast
Calcineurin nephrotoxicity.
@en
type
label
Calcineurin nephrotoxicity.
@ast
Calcineurin nephrotoxicity.
@en
prefLabel
Calcineurin nephrotoxicity.
@ast
Calcineurin nephrotoxicity.
@en
P1476
Calcineurin nephrotoxicity.
@en
P2093
David Williams
Lukas Haragsim
P356
10.1053/J.ACKD.2005.11.001
P577
2006-01-01T00:00:00Z